New Business Models Needed For Drug Diagnostic Partnerships
This article was originally published in The Pink Sheet Daily
Executive Summary
The industry is stymied by outmoded partnership models that don’t adequately value the knowledge of diagnostic makers.
You may also be interested in...
Drug, Diagnostic Firms Should Partner, Not Merge, To Personalize Medicine
The drug and diagnostic industries should partner, not merge, to develop companion products, according to a diagnostics industry representative on a recent Personalized Medicine Coalition conference panel
Riquent Trial Fails; Is This La Jolla’s Last Gasp?
Data monitoring board says continuing ASPEN trial is “futile” after first interim look at BioMarin-licensed Riquent trial for treatment of lupus nephritis.
Genentech Rituxan Failed Lupus Trial Also Takes Down Ocrelizumab For SLE
Genentech is abandoning development of both its anti-CD20 monoclonal antibodies for systemic lupus erythematosus after the failure of Rituxan (rituximab) in the Phase II/III EXPLORER trial cast doubt on the validity of targeting the CD20 antigen on B-cells as an approach to SLE.